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Abstract: Parkinson’s Disease (PD) and alpha synucleinopathies are multifactorial disorders, which manifest through 
motor symptoms and non-motor symptoms involving the Central Nervous System (CNS), the Peripheral Nervous System 
(PNS) and, recently, also the Enteric Nervous System (ENS). The typical hallmarks of these pathologies are known as 
Lewy Bodies (LBs) and Lewy Neurites (LNs), alpha synuclein (αS) proteinaceous, discovered in dopaminergic neurons of 
substantia nigra (pars compacta) as well as in other regions of the central and peripheral nervous systems. Despite the 
clear causes which lead to LBs/LNs are still unknown, according to Braak’s theory, these inclusions appear first in PNS to 
spread, following neuronal innervation, towards the CNS. In line with these observations, several animal models have 
been used with the purpose to reproduce PD as well as to propose new therapeutic approaches. The present review 
highlights αS as the key-word for PD pathology and a main target in PD research, focusing on ER-stress and innovative 
immunotherapy, which could be a  promising tool to reduce neuronal degeneration and to halt PD progression. 
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1. INTRODUCTION 
 Parkinson’s Disease (PD) is the second most common 
neurodegenerative disorder after Alzheimer‘s Disease (AD). 
Until now, two forms of the pathology have been discovered: 
an idiopathic form also named “sporadic Parkinson’s 
disease” to indicate its unknown origin and a second genetic 
form also recognized as “Familial Parkinson’s disease” [1]. 
Although the clear etiology is still unknown, degenerating 
neuronal populations in PD exhibits the accumulation of 
abundant intraneuronal inclusions known as Lewy 
bodies/Lewy neurites (LBs/LNs) containing the misfolded 
fibrillar protein alpha synuclein (αS) [2]. 
1.1. Principal features of αS protein 
The αS protein is a 140 amino acid comprising peptide and a 
member of the synuclein family that also includes βS and γS. 
The amino acidic sequence of αS is characterized by an N-
terminal amphipatic domain (1-60), a hydrophobic core 
denoted as non-Aβ component of Alzheimer disease amyloid 
(NAC, 61-95) and an acidic C-terminal negatively charged 
region (96-140) [3,4] (Fig. 1).  
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This protein is typically localized in the cytosol but the 
propensity of its N-terminal region to bind specific lipid 
rafts, enriched in cholesterol and sphingolipids, locates αS 
also in plasma membrane [5–8] as well as in sub-cellular 
compartments such as mitochondria [9]. The enrichment of 
αS in presynaptic terminals has led to the assumption that the 
protein is involved in the regulation of synaptic transmission, 
synaptic plasticity and neurotransmitter synthesis [10,11]. 
Moreover, in line with these observations, αS has been found 
to participate in the recycle of synaptic vesicles [12].  
The native αS is unfolded, but under pathological conditions 
can undergo conformational changes, truncation, 
oligomerization, post-translational modification such as 
ubiquitination, hyperphosphorylation, nitration and oxidation 
and turns onto a β-sheet pathological structure, thus forming 
aggregates and becoming insoluble [13–15]. Point mutations 
(A30P, A53T and E46K) or gene amplifications of αS have 
been identified in familiar pedigree as responsible for the 
early onset of PD, suggesting that αS abnormalities are 
linked to pathogenesis of PD and other α-synucleinopathies 
[16–19]. Several studies have demonstrated that αS forms 
aggregates in a nucleation-dependent manner, where first 
soluble αS monomers forms soluble oligomers or protofibrils 
and, after a series of drastic conformational changes, they











Figure (1). Primary amino acidic sequence of αS. The αS protein is made up by 140 amino acids. It is structurally characterized by three main regions: the 
N-terminal region containing the three point missens mutations (A30P, E46K, A53T) responsible of the early onset of PD also responsible for the binding 
with lipid membranes; the NAC central hydrophobic region important for  the protein oligomerization and the C-terminal acidic region  which can be subject 
of post translational modifications. 
 
serve as nuclei to evolve into insoluble fibrils within cells 
[18]. It is not entirely clear which αS-aggregated form is 
cytotoxic and if the LBs/LNs are a cellular protective 
strategy to sequester αS aggregates avoiding the health cell 
impairment [20] (Fig. 2). However, the hypothetical “toxic 
aggregates” are responsible for the unbalance between 
physiological and pathological αS proteins. In fact, an ever 
increasing body of evidence demonstrates that in vitro and in 
vivo formed αS monomer and fibrils are internalized by cells 
and may be propagated in a prion-like manner leading to 
endogenous αS aggregation and neurotoxicity [4]. Studies by 
Desplates and coworkers have shown how populations of 
human dopaminergic (DA) neuron cells (derived from SH-
SY5Y neuroblastoma cells) were capable of taking up αS 
aggregates via endocytosis from neighboring neurons, 
forming, in turn, Lewy-like inclusions. Furthermore, these 
authors demonstrated that a directed host-to-graft 
transmission of misfolded αS occurs in vivo using a 
transgenic model of PD [21]. Other authors have also 
observed that the in vitro αS pre-formed fibrils (PFFs) are 
able to efficiently induce the aggregation and fibrillization of 
soluble endogenous αS in primary neuronal cultures 
generated from wild type (WT) mice [19,22,23]. It has been 
subsequently found that a single intra-striatal inoculation of 
pre-formed αS fibrils in WT non transgenic mice led to the 
cell-to-cell transmission of pathological αS, accumulation of 
intracellular LB/LN pathology and selective loss of DA 
neurons in anatomically interconnected regions [24]. 
Importantly, αS aggregates play another interesting role in 
triggering PD neurodegeneration. In particular, several 
studies have revealed that the transmission of neuronal αS 
aggregates takes place not only through a neuron-to-neuron 
interaction mechanism but also involving adjacent 
astrocytes. The αS astrocyte inclusions are probably 
addressed to a lysosomal sorting for their degradation 
[25,26]. Nevertheless, the persistence of neuronal αS 
aggregates provokes their accumulation in glial cytosol, 
triggering the release of pro inflammatory mediators such as 
cytokines and chemokines and inducing an inflammatory 
response as well as the activation of microglia, which is 
supposed to enhance neurodegeneration [27,28]. 
2. BRAAK’S THEORY 
 In agreement with this line, Braak and coworkers 
elaborated a theory based on neuropathological analysis of 
human brains of PD cases. According to these findings, 
initial LBs appearance occurs in locations no classically 
linked to PD such as the dorsal motor nucleus of the 
glossopharyngeal, vagal nerves and anterior olfactory 
nucleus and even the neuronal innervation of the gut. From 
those first locations, the LB pathology then progresses to 
higher brain centers following the vague innervation in a 
predictable ascending manner to the midbrain and finally to 
the basal forebrain and neocortex [29–32]. Detailed analysis 
of human brain samples allowed Braak and coworkers to 
distinguish six stages in the disease progression, including 
stages 1 and 2 where the pathology is still asymptomatic and 
LBs are spread only in peripheral areas, medulla 
oblongata/pontine tegmentum, in anterior olfactory 
structures and in the Enteric Nervous System (ENS). In stage 
3 and 4, classical PD motor symptoms become apparent and 
the pathology reaches the midbrain, including substantia 
nigra; stage 5 and 6 are instead characterized by the 
involvement of neocortical regions in association with 
cognitive impairment [33–35]. Dissemination of LB 
pathology and neurodegeneration in areas outside the 
substantia nigra can also explain the incidence of non-motor 
symptoms that affect PD patients. Some of these symptoms, 
such as a reduced sense of smell, gastrointestinal (GI) 
dysfunction including salivation, dysphagia, impaired gastric 



















Figure (2). Hypotetical mechanism of αS amyloid fibrils formation and in vitro/in vivo trasmission of αS toxic aggregates. The native unfolded αS turns onto a 
folded or misfolded form having a high propensity of self aggregation into oligomers in a reversible process (double arrows). In a next step, oligomers 
continue to aggregate in a nucleation dependent manner until forming  protofibrils and amyloid fibrils. In the latest process,  reversibility is drastic reduced and 
misfolded αS is confined in the Lewis bodies. The αS oligomers and protofibrils could be the toxic aggregates, responsible for the cell-to-cell transmission of 
the Lewis bodies as demonstrated by in vitro and in vivo studies. 
 
empting and defecatory dysfunction have been found to 
precede the development of somatic motor symptoms for 
decades before the disease’s manifestation [36,37]. In fact, 
about 60% of PD patients have complained sustained 
constipation and GI dysfunction for long time before 
developing motor symptoms related to PD [38,39]. To 
confirm these findings, Holmqvist and coworkers have 
recently shown that different forms of αS from PD patient 
brain lysates, injected in the wall of the rat GI tract, in close 
proximity to the myenteric plexus, are transported 
retrogradely via the vagal nerves from the gut to the brain 
and that microtubule associated transport is involved in this 
propagation [40]. 
3. ANIMAL MODELS OF PD 
 Several animal models have been used to study PD, from 
unicellular eukaryote organisms such as the yeast 
Saccharomyces cerevisiae, or pluricellular ones as the 
nematode Caenorhabditis elegans and the fruit fly 
Drosophila melanogaster, to the evolutionarily similar non-
human primates [41–43]. However, these models present 
obvious limits: yeasts or flies cannot suitably reproduce the 
loss of neurons in the brain typical of PD, while non-human 
primates present limitations in terms of costs and ethical 
concerns. Thus, because of their similarities to humans and 
these multiplicity of factors, rodent model is the most widely 
used to investigate PD [44]. To date, there are no rodent 
models that can reproduce completely the pathophysiology 
of PD. However, both the pharmacological and genetic 
models are frequently used not only to identify triggers and 
mechanisms of disease onset but also to develop strategies to 
stop neurodegeneration. The pharmacological model 
involves environmental toxins such as 6-hydroxydopamine 
(6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), paraquat or rotenone [45–47]. The second one is 
characterized by the transgenic over-expression of mutant 
autosomal dominant genes such as αS or leucine-rich-repeat 
kinase 2 (LRRK2), and knockout or knockdown models for 
autosomal recessive genes such as Parkin, DJ-1, PINK1 [48]. 
In particular, regarding the autosomal dominant mutations of 
αS gene, three missens point mutations have been identified 
in the early-onset of PD: A30P, E46K and A53T followed by 
the corresponding transgenic mouse models [49]. 
Specifically, Lee and coworkers have obtained an A53T αS 
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transgenic mouse model under the control of the mouse 
prion protein promoter (PrP). This model displays a robust 
neurodegeneration phenotype characterized by an adult onset 
of the pathology coupled with αS fibrillar accumulation in 
neurons and perikarya, astroglial reaction in affected brain 
regions and progressive motor dysfunction leading to death. 
Moreover, the same model is also associated with 
mitochondrial DNA damage, apoptosis of neocortical, 
brainstem and motor neurons [50]. Intriguingly, Kuo and 
coworkers have shown that A53T or A30P αS transgenic 
mouse models present ENS dysfunctions at a young age, 
before the onset of others non-motor symptoms such as the 
dysfunction in olfaction or changes in the brain stem and the 
dorsal motor nucleus of the vagal nerve (DMV) [51]. 
Thus, despite the pharmacological-based models are 
effective in showing a selective loss of DA neurons, they fail 
to replicate all the pathological features of PD such as the 
progressive changes in the brain and the onset of symptoms 
in the time. From this point of view, genetic models are more 
effective, they show a gradual progression of the pathology 
which allows to administer a therapeutic treatment prior the 
onset of the symptoms and to identify an hypothetical early 
biomarker . 
4. THERAPEUTIC CHALLENGE 
 In the last years, scientific research on PD has focused 
his attention on identifying appropriate targets to which 
address new therapies. The protein S seems to be the most 
promising key factor to investigate. Among the several 
therapeutic approaches, it could be farsighted acting on two 
levels (Fig. 3): 
 - at the intracellular level, to reduce αS toxic species 
which probably impair the balance between the αS functional 
forms and toxic aggregates, these last interestingly 
considered in some studies as protective forms [52] (Fig. 2); 
 - at the extracellular level, to circumvent αS cell-to-cell 
transmission and glial activation, leading to chronic 
inflammation, another pathological feature of PD [53,26]. 
4.1. ER/mitochondrial dysfunction and oxidative stress in 
PD: a considerable pathological pathway and a 
reasonable therapeutic target 
 The involvement of mitochondrial dysfunction in PD has 
been much dependent from the discovery of 1- methyl – 4 – 
phenyl- 1,2,3,6 – tetrahydropyridine (MPTP), followed by 
paraquat and rotenone, as potent and selective inhibitors of 
complex 1 of the respiratory chain. The use of these drugs 
result in the impairment of ATP synthesis and in the increase 
of oxygen free radicals (ROS), leading to oxidative stress 
[54]. Several mutations of mitochondrial DNA, encoding 
some respiratory chain factors, have been also correlated to 
complex 1 defects in PD [55]. Moreover, oxidative stress 
could be responsible for the accumulation of unfolded or 
mis-folded proteins such as αS at the intracellular level. In 
fact, the accumulation of mis-folded αS can disrupt the 
activity of another intracytoplasmic organelle, the 
Endoplasmic Reticulum (ER), involved in protein synthesis, 
glycosilation and folding, leading to the Unfolded Protein 
Response (UPR) [56,57]. This latest is a physiological 
protective response which stimulates a specific apoptotic 
pathway through the activation of the transcription factor 
C/EBP homologous protein (CHOP). The response also 
includes the inhibition of protein synthesis via the 
phosphorylation of the eukaryotic initiation factor 2α (eIF2α) 
[58–60].  
To verify whether ER stress is involved in αS 
neurodegeneration in vivo, Colla and coworkers have 
reported that αS oligomers displaying the toxic conformation 
precede the onset of α-synucleinopathy and their 
accumulation in neuronal ER/mitochondria of humans as 
well as in A53T human αS mice, responsible of ER-stress 
induced apoptosis [61]. From these findings, the authors 
have hypothesized a possible evolution mechanism of αS 
abnormalities in ER/mitochondria: the αS flux toward the 
ER/mitochondria lumen increases with aging or the disease. 
It is made up by the presence of low initial levels of αS, then 
by immature soluble oligomers in the lumen, until they 
become detergent-insoluble macro aggregates/fibrils. The 
insoluble aggregates become exposed to the cytosol, 
probably by destabilizing the membranes, leading to ER 
stress, cell dysfunction and neurodegeneration (Fig. 3). This 
hypothesis has also been confirmed by the use of Salubrinal, 
an anti-ER stress compound, which promotes 
dephosphorylation of eIF2α and increases CHOP, the 
downstream reporter for p-eIF2α. This treatment showed a 
decrease of ER/mitochondria associated toxic αS oligomers, 
a delay of the pathological onset and a life span extension of 
A53T αS mice [62,63]. 
In addition, Laguarta and coworkers explained the 
localization of αS in mitochondria – associated ER 
membranes (MAM), a sub-region of the ER that connects 
mitochondria to the ER, involved in cholesterol and 
phospholipid metabolism. Alterations in MAM-localized 
proteins or in MAM functions play a role in 
neurodegenerative disease. As reported by Laguarta: “in the 
case of PD, point mutations of αS resulted in its reduced 
association with MAM, a lower degree of apposition of ER 
with mitochondria and a decrease in MAM function causing 
an increase in mitochondrial fragmentation compared with 
WT αS”[64]. These findings are relevant because they have 
identified potential sites for a therapeutic intervention. 
4.2. New frontiers in PD: the immunotherapy 
 An alternative and innovative therapeutic approach, 
which could be ad hoc to target “toxic αS aggregates”, uses 
immunotherapy. It has been widely applied for cancer, HIV, 
but recently his attention pointed towards neurodegenerative 
disorders. Several studies focus on Huntington, Alzheimer 
and Prion’s diseases, but a therapeutic intervention in α-
synucleinopathies has been largely overlooked due to the 
pathological complexity and the uncertainty of the 
pathogenesis [65]. The use of immunotherapy in 
neurodegenerative disorders has been reinforced by the 
results from passive immunization against -amyloid (Aβ) 
using monoclonal antibody (mAb) in AD, which has reached 



















Figure (3). A model of proposed therapeutic strategies shown in cartoon form. The use of Salubrinal (1) reduces intracellular ER/M stress and the formation of 
toxic oligomers. Immunotherapy (2) (represented by mAb and intrabodies) can act on two levels: it provides the clearence of toxic aggregates present in the 
extracellular environment reducing their cell-to-cell transmission or the glial activation; it can also act intracellularly using intra-bodies which recognize 
specific conformational targets, modulating their effect. 
 
phase III clinical trials [66]. Since Kohler and Milstein 
discovered the mAb technology [67], numerous 
advancements have been done passing through different 
engineered antibodies, until to discover the single chain 
antibody fragment (scFv). The use of scFv demonstrates 
multiple advantages including its application as intracellular 
antibodies or intra-bodies addressed to an intracellular target 
in order to modulate its function. Precisely, Meli and 
coworkers generated conformational sensitive antibodies 
with the aim of intercepting in vitro Aβ toxic oligomers 
(AβOs), crucial players in Alzheimer Disease (AD), in a 
subcellular compartment such as the ER. Of note, this tool 
shows a prominent aspect thanks to which is possible to 
target critical AβOs conformers inside the ER without 
interfering with the maturation and processing of the Aβ 
precursor protein (APP) [68,69]. 
As described previously, αS aggregates in PD have been 
associated with ER/mitochondria in human brain and in the 
A53T αS transgenic mouse model of PD. The use of a 
conformational intra-body against the αS toxic aggregates in 
a subcellular compartment could provide their clearance 
other than symptoms’ improvement. Some studies [70–72] 
focused their attention on intra-bodies targeted directly to the 
brain, when the disease is already in an advanced 
neurodegenerative stage. However, the challenge could be to 
address conformational sensitive intra-bodies against αS to 
an early disease target such as the gut, when the pathology is 




 The primary cause of Parkinson’s disease is still 
unknown but numerous advancements have been done to a 
better understanding of the pathology. Despite the plethora 
of studies about the expression of αS, and the loss of DA 
neurons in the CNS, less information focused their attention 
on αS expression in the PNS or the ENS and its implications 
on patient’s life. The studies mentioned in this review 
support the idea of using early biomarkers such as those 
localized in the GI tract, not only to anticipate PD diagnosis 
but also to intervene with innovative treatments contrasting 
the formation of αS aggregates and their cytotoxicity as well 
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as, according to Braak’s theory, to avoid or to delay the 
ascendant progression of Lewy body’s lesions to the CNS. 
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